Department of Pharmacology and Physiology, GW Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Adv Exp Med Biol. 2019;1164:119-139. doi: 10.1007/978-3-030-22254-3_10.
Alternative splicing, the process of removing introns and joining exons of pre-mRNA, is critical for growth, development, tissue homeostasis, and species diversity. Dysregulation of alternative splicing can initiate and drive disease. Aberrant alternative splicing has been shown to promote the "hallmarks of cancer" in both hematological and solid cancers. Of interest, recent work has focused on the role of alternative splicing in prostate cancer and prostate cancer health disparities. We will provide a review of prostate cancer health disparities involving the African American population, alternative RNA splicing, and alternative splicing in prostate cancer. Lastly, we will summarize our work on differential alternative splicing in prostate cancer disparities and its implications for disparate health outcomes and therapeutic targets.
选择性剪接是一种去除前体 mRNA 内含子并连接外显子的过程，对于生长、发育、组织稳态和物种多样性至关重要。选择性剪接的失调会引发和驱动疾病。已经证明，异常的选择性剪接会促进血液系统和实体瘤中的“癌症特征”。值得注意的是，最近的工作集中在选择性剪接在前列腺癌和前列腺癌健康差异中的作用。我们将回顾涉及非裔美国人的前列腺癌健康差异、RNA 选择性剪接和前列腺癌中的选择性剪接。最后，我们将总结我们在前列腺癌差异中的差异选择性剪接及其对不同健康结果和治疗靶点的影响的工作。
